The partnership creates a significant financial pipeline for Tempus AI, which will receive $192.5 million in cash commitments over the next five years. This total includes a $137.5 million direct contribution from Bristol Myers alongside a separate $55 million payment from Pathos AI. The latter transaction covers the acquisition of 500,000 de-identified patient records to fuel research into neurological conditions.
In section Market Quotes
Tempus AI and Bristol Myers Deepen Oncology Data Partnership
Bristol Myers Squibb has secured a multi-year agreement to leverage the Lens Platform from Tempus AI, integrating the company’s agentic artificial intelligence into its oncology drug development pipeline through 2031. The deal aims to accelerate clinical insights and target discovery by utilizing Tempus’s vast library of real-world multimodal datasets.
Pathos AI, which recently secured a $237 million Series E funding round led by Bristol Myers at a $3 billion valuation, is also expanding its own integration with both firms. This three-way collaboration focuses on building specialized, curated datasets for Alzheimer’s disease and other neurological disorders, granting Bristol Myers broader access to the Pathos Foundry AI platform.
Comments (0)
No comments yet. Be the first!